LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today announced that Timothy Barberich has been appointed to its Board of Directors.
Research findings offer promising treatment target for blinding diseases
New research published in Cell Reports identifies a potential treatment target for blinding diseases such as retinitis pigmentosa and advanced dry age-related macular degeneration.
Head-mounted display did not have significant clinical effect on normal eyes
Volunteers who watched video using a head-mounted display for 30 minutes did not experience significant clinical effects in their normal adolescent eyes, according to a study. The study, completed at Korea University College of Medicine in Seoul, inclu…
Senate approves $1.1b in Zika funding as part of stopgap spending bill
The Senate on Wednesday passed a bill to keep the federal government running through Dec. 9, including $1.1 billion in long-awaited emergency funding for prevention and treatment of the Zika virus, according to reports.The 72-26 vote came just 2 days b…
Cellular Dynamics International launches Opsis Therapeutics to develop retinal disease treatments
Cellular Dynamics International has launched Opsis Therapeutics, a new project aimed at discovering and developing medicines for patients with retinal diseases, according to a company press release.CDI, which develops and manufactures induced pluripotent stem cell (iPSC) products, formed Opsis Therapeutics to focus on researching and manufacturing new retinal disease treatments with a “cross-disciplinary team of internationally recognized advisors and development partners,” the release said. These partners have experience in iPSC manufacture, iPSC differentiation into retinal lineages, retinal cell biology, preclinical modeling of retinal disease and subretinal surgery.
On-Site, Telemedicine Views on Infants’ Eyes May Differ
Evaluating acute-phase retinopathy of prematurity (ROP) by direct clinical examination may produce different results from evaluations done via telemedicine, according to new findings. Reuters Health Information